The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy

Congqi Shi; Kaiyu Qin; Anqi Lin; Aimin Jiang; Quan Cheng; Zaoqu Liu; Jian Zhang; Peng Luo

doi:10.1186/s13046-022-02469-0

journal article Open Access Sep 07, 2022

The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy

Congqi Shi Kaiyu Qin Anqi Lin

Journal of Experimental & Clinical Cancer Research Vol. 41 No. 1 · Springer Science and Business Media LLC

View at Publisher Save 10.1186/s13046-022-02469-0

Abstract

AbstractAs our understanding of the mechanisms of cancer treatment has increased, a growing number of studies demonstrate pathways through which DNA damage repair (DDR) affects the immune system. At the same time, the varied response of patients to immune checkpoint blockade (ICB) therapy has prompted the discovery of various predictive biomarkers and the study of combination therapy. Here, our investigation explores the interactions involved in combination therapy, accompanied by a review that summarizes currently identified and promising predictors of response to immune checkpoint inhibitors (ICIs) that are useful for classifying oncology patients. In addition, this work, which discusses immunogenicity and several components of the tumor immune microenvironment, serves to illustrate the mechanism by which higher response rates and improved efficacy of DDR inhibitors (DDRi) in combination with ICIs are achieved.

Topics

No keywords indexed for this article. Browse by subject →

References

252

[1]

Marconcini R, Spagnolo F, Stucci LS, Ribero S, Marra E, de Rosa F, et al. Current status and perspectives in immunotherapy for metastatic melanoma. Oncotarget. 2018;9:12452–70 Impact Journals LLC. Available from: https://pubmed.ncbi.nlm.nih.gov/29552325. Accessed 11 Aug 2021. 10.18632/oncotarget.23746

[2]

Si Y, Lin A, Ding W, Meng H, Luo P, Zhang J. CARD11 alteration as a candidate biomarker of skin cutaneous melanoma treated with immune checkpoint blockade. Am J Transl Res. 2021;13:286–300 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847528/. Accessed 15 June 2022.

[3]

Lin W, Lin A, Li Z, Zhou C, Chen C, Chen B, et al. Potential predictive value of SCN4A mutation status for immune checkpoint inhibitors in melanoma. Biomed Pharmacother. 2020;131:110633 Available from: http://www.ncbi.nlm.nih.gov/pubmed/32892029. Accessed 14 June 2022. 10.1016/j.biopha.2020.110633

[4]

Nolan E, Savas P, Policheni AN, Darcy PK, Vaillant F, Mintoff CP, et al. Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer. Sci Transl Med. 2017;9 Available from: http://stm.sciencemag.org/. Accessed 9 Sept 2021. 10.1126/scitranslmed.aal4922

[5]

Parker C. A near miss for prostate cancer immunotherapy. Lancet Oncol. 2014;15:669–71 Available from: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70220-7/fulltext. Accessed 7 Sept 2021. 10.1016/s1470-2045(14)70220-7

[6]

Goetze TO. Immunotherapy: a new era in small-cell lung cancer. Lancet J. 2019;394:1884–5. Available from: https://doi.org/10.1016/S0140-6736(19)32235-4 Accessed 7 Sept 2021. 10.1016/s0140-6736(19)32235-4

[7]

Souquet P-J, Couraud S. Immune checkpoint inhibitors: a game changer for metastatic non-small-cell lung cancer. Lancet Oncol. 2019;20:1334–5 Available from: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30508-X/fulltext. Accessed 7 Sept 2021. 10.1016/s1470-2045(19)30508-x

[8]

Lin A, Zhang H, Hu X, Chen X, Wu G, Luo P, et al. Age, sex, and specific gene mutations affect the effects of immune checkpoint inhibitors in colorectal cancer. Pharmacol Res. 2020;159:105028. https://doi.org/10.1016/j.phrs.2020.105028 Accessed 23 Aug 2021. 10.1016/j.phrs.2020.105028

[9]

Sen T, Rodriguez BL, Chen L, della Corte CM, Morikawa N, Fujimoto J, et al. Targeting DNA damage response promotes anti-tumor immunity through STING-mediated T-cell activation in small cell lung cancer. Cancer Discov. 2019;9:646–61. Available from: https://doi.org/10.1158/2159-8290.CD-18-1020 American Association for Cancer Research Inc. Accessed 2 Sept 2021. 10.1158/2159-8290.cd-18-1020

[10]

Tang Z, Pilié PG, Geng C, Manyam GC, Yang G, Park S, et al. ATR inhibition induces CDK1-SPOP signaling and enhances anti-PD-L1 cytotoxicity in prostate cancer. Clin Cancer Res. 2021;27:4898–909 American Association for Cancer Research Inc. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8456453/. Accessed 11 Jan 2022. 10.1158/1078-0432.ccr-21-1010

[11]

Subudhi SK, Vence L, Zhao H, Blando J, Yadav SS, Xiong Q, et al. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci Transl Med. 2020;12:3577 Available from: https://pubmed.ncbi.nlm.nih.gov/32238575/. Accessed 7 Sept 2021. 10.1126/scitranslmed.aaz3577

[12]

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al.

New England Journal of Medicine 2012 10.1056/nejmoa1200690

[13]

Sharma P, Pachynski RK, Narayan V, Fléchon A, Gravis G, Galsky MD, et al. Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial. Cancer Cell. 2020;38:489–499.e3 Cell Press. Available from: https://www.cell.com/cancer-cell/pdf/S1535-6108(20)30418-9.pdf. Accessed 11 Aug 2021. 10.1016/j.ccell.2020.08.007

[14]

Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18:345–62 Nature Research. Available from: https://www.nature.com/articles/s41571-021-00473-5. Accessed 11 Sept 2021. 10.1038/s41571-021-00473-5

[15]

Dudley JC, Lin MT, Le DT, Eshleman JR. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res. 2016;22:813–20 American Association for Cancer Research Inc. Available from: https://aacrjournals.org/clincancerres/article/22/4/813/251220/Microsatellite-Instability-as-a-Biomarker-for-PD-1?searchresult=1. Accessed 19 Sept 2021. 10.1158/1078-0432.ccr-15-1678

[16]

Lamberti G, Andrini E, Sisi M, di Federico A, Ricciuti B. Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication. Future Oncol. 2020;16:1751–66 Future Medicine Ltd. Available from: https://www.futuremedicine.com/doi/full/10.2217/fon-2020-0215. Accessed 12 Sept 2021. 10.2217/fon-2020-0215

[17]

Lhuillier C, Vanpouille-Box C, Galluzzi L, Formenti SC, Demaria S. Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers. Semin Cancer Biol. 2018;52:125–34 Academic Press. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6004231/. Accessed 24 Aug 2021. 10.1016/j.semcancer.2017.12.007

[18]

Klein O, Kee D, Markman B, Carlino MS, Underhill C, Palmer J, et al. Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy. Cancer Cell. 2021;39:592–3 Cell Press. Available from: https://www.sciencedirect.com/science/article/pii/S1535610821002130. Accessed 11 Sept 2021. 10.1016/j.ccell.2021.04.005

[19]

Lin A, Zhang J, Luo P. Crosstalk between the MSI status and tumor microenvironment in colorectal cancer. Front Immunol. 2020;11:2039 Available from: http://www.ncbi.nlm.nih.gov/pubmed/32903444. Accessed 14 June 2022. 10.3389/fimmu.2020.02039

[20]

Xiong A, Nie W, Zhou Y, Li C, Gu K, Zhang D, et al. Comutations in DDR pathways predict Atezolizumab response in non-small cell lung cancer patients. Front Immunol. 2021;12:708558 Available from: http://www.ncbi.nlm.nih.gov/pubmed/34630387. Accessed 12 Jan 2022. 10.3389/fimmu.2021.708558

[21]

Gettinger S, Rizvi NA, Chow LQ, Borghaei H, Brahmer J, Ready N, et al. Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2016;34:2980–7 American Society of Clinical Oncology. Available from: https://ascopubs.org/doi/10.1200/JCO.2016.66.9929. Accessed 9 Feb 2022. 10.1200/jco.2016.66.9929

[22]

de Bono JS, Goh JCH, Ojamaa K, Piulats Rodriguez JM, Drake CG, Hoimes CJ, et al. KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2018;36(Suppl 15):5007. https://doi.org/10.1200/JCO.2018.36.15_suppl.5007 Wolters Kluwer. Accessed 15 Sept 2021. 10.1200/jco.2018.36.15_suppl.5007

[23]

Ribas A. Releasing the brakes on cancer immunotherapy. N Engl J Med. 2015;373:1490–2 New England Journal of Medicine (NEJM/MMS). Available from: https://www.nejm.org/doi/full/10.1056/NEJMp1510079. Accessed 10 Feb 2022. 10.1056/nejmp1510079

[24]

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Dung T. Le, Jennifer N. Uram, Haitao Wang et al.

New England Journal of Medicine 2015 10.1056/nejmoa1500596

[25]

A molecular portrait of microsatellite instability across multiple cancers

Isidro Cortés-Ciriano, Sejoon Lee, Woong-Yang Park et al.

Nature Communications 2017 10.1038/ncomms15180

[26]

Ettrich TJ, Seufferlein T. Systemic therapy for metastatic pancreatic cancer. Curr Treat Options in Oncol. 2021;22:106 Springer. Available from: https://link.springer.com/article/10.1007/s11864-021-00895-4. Accessed 10 Feb 2022. 10.1007/s11864-021-00895-4

[27]

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

Aurelien Marabelle, Dung T. Le, Paolo A. Ascierto et al.

Journal of Clinical Oncology 2020 10.1200/jco.19.02105

[28]

Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008;8:193–204. Available from: https://doi.org/10.1038/nrc2342 Accessed 14 Mar 2022. 10.1038/nrc2342

[29]

Sancar A, Lindsey-Boltz LA, Ünsal-Kaçmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem. 2004;73:39–85. Available from: https://doi.org/10.1146/annurev.biochem.73.011303.073723 Accessed 14 Mar 2022. 10.1146/annurev.biochem.73.011303.073723

[30]

Luo P, Lin A, Li K, Wei T, Zhang J. DDR pathway alteration, tumor mutation burden, and cisplatin sensitivity in small cell lung cancer: difference detected by whole exome and targeted gene sequencing. J Thorac Oncol. 2019;14:e276–9 Available from: http://www.ncbi.nlm.nih.gov/pubmed/31757380. Accessed 14 June 2022. 10.1016/j.jtho.2019.08.2509

[31]

Knijnenburg TA, Wang L, Zimmermann MT, Chambwe N, Gao GF, Cherniack AD, et al. Genomic and molecular landscape of DNA damage repair deficiency across The Cancer Genome Atlas. Cell Rep. 2018;23:239–254.e6. Available from: https://doi.org/10.1016/j.celrep.2018.03.076 Cell Press. Accessed 30 Apr 2022. 10.1016/j.celrep.2018.03.076

[32]

Yu EY, Wu H, Schloss C. KEYNOTE-365: phase 1b/2 trial of pembrolizumab combination therapy for metastatic castration-resistant prostate cancer (mCRPC). Eur Urol Suppl. 2017;16:e360 Available from: https://www.sciencedirect.com/science/article/pii/S1569905617302749. Accessed 9 Jan 2022. 10.1016/s1569-9056(17)30274-9

[33]

Karzai F, Vanderweele D, Madan RA, Owens H, Cordes LM, Hankin A, et al. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. J Immunother Cancer. 2018;6:141. Available from: https://doi.org/10.1186/s40425-018-0463-2 BioMed Central Ltd. Accessed 23 Aug 2021. 10.1186/s40425-018-0463-2

[34]

Zhou C, Lin A, Cao M, Ding W, Mou W, Guo N, et al. Activation of the DDR pathway leads to the down-regulation of the TGFβ pathway and a better response to ICIs in patients with metastatic urothelial carcinoma. Front Immunol. 2021;12 Frontiers Media S.A. Available from: https://www.frontiersin.org/articles/10.3389/fimmu.2021.634741/full. Accessed 11 Sept 202. 10.3389/fimmu.2021.634741

[35]

Qing T, Jun T, Lindblad KE, Lujambio A, Marczyk M, Pusztai L, et al. Diverse immune response of DNA damage repair-deficient tumors. Cell Rep Med. 2021;2:100276. Available from: https://doi.org/10.1016/j.xcrm.2021.100276 Accessed 11 Sept 2021. 10.1016/j.xcrm.2021.100276

[36]

Parkes EE, Walker SM, Taggart LE, McCabe N, Knight LA, Wilkinson R, et al. Activation of STING-dependent innate immune signaling by s-phase-specific DNA damage in breast cancer. J Natl Cancer Inst. 2017;109 Oxford University Press. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5441301/. Accessed 6 Oct 2021. 10.1093/jnci/djw199

[37]

Shen T, Jia S, Ding G, Ping D, Zhou L, Zhou S, et al. BxPC-3-derived small extracellular vesicles induce FOXP3+ Treg through ATM-AMPK-Sirtuins-mediated FOXOs nuclear translocations. iScience. 2020;23:101431 Available from: http://www.ncbi.nlm.nih.gov/pubmed/32798974. Accessed 8 Dec 2021. 10.1016/j.isci.2020.101431

[38]

Peyraud F, Italiano A. Combined PARP inhibition and immune checkpoint therapy in solid tumors. Cancers (Basel). 2020;12 Available from: http://www.ncbi.nlm.nih.gov/pubmed/32526888. Accessed 8 Nov 2021. 10.3390/cancers12061502

[39]

Ricciuti B, Recondo G, Spurr LF, Li YY, Lamberti G, Venkatraman D, et al. Impact of DNA damage response and repair (DDR) gene mutations on efficacy of PD-(L)1 immune checkpoint inhibition in non–small cell lung cancer. Clin Cancer Res. 2020;26:4135–42 American Association for Cancer Research Inc. Available from: https://aacrjournals.org/clincancerres/article/26/15/4135/82560/Impact-of-DNA-Damage-Response-and-Repair-DDR-Gene. Accessed 12 Sept 2021. 10.1158/1078-0432.ccr-19-3529

[40]

Chabanon RM, Rouanne M, Lord CJ, Soria JC, Pasero P, Postel-Vinay S. Targeting the DNA damage response in immuno-oncology: developments and opportunities. Nat Rev Cancer. 2021;21:701–17 Nature Research. Available from: https://www.nature.com/articles/s41568-021-00386-6. Accessed 15 Mar 2022. 10.1038/s41568-021-00386-6

[41]

Huang JL, Chang YT, Hong ZY, Lin CS. Targeting DNA damage response and immune checkpoint for anticancer therapy. Int J Mol Sci. 2022;23:3238 Available from: http://www.ncbi.nlm.nih.gov/pubmed/35328658. Accessed 15 June 2022. 10.3390/ijms23063238

[42]

Hopkins JL, Lan L, Zou L. DNA repair defects in cancer and therapeutic opportunities. Genes Dev. 2022;36:278–93 Available from: http://www.ncbi.nlm.nih.gov/pubmed/35318271. Accessed 15 June 2022. 10.1101/gad.349431.122

[43]

Wang Y, Duan M, Peng Z, Fan R, He Y, Zhang H, et al. Advances of DNA damage repair-related drugs and combination with immunotherapy in tumor treatment. Front Immunol. 2022;13. Available from: https://doi.org/10.3389/fimmu.2022.854730 Frontiers Media S.A. Accessed 15 June 2022. 10.3389/fimmu.2022.854730

[44]

Pilger D, Seymour LW, Jackson SP. Interfaces between cellular responses to DNA damage and cancer immunotherapy. Genes Dev. 2021;35:602–18 Cold Spring Harbor Laboratory Press. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8091970/. Accessed 1 Aug 2021. 10.1101/gad.348314.121

[45]

Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers

Min Yuen Teo, Kenneth Seier, Irina Ostrovnaya et al.

Journal of Clinical Oncology 2018 10.1200/jco.2017.75.7740

[46]

Banchereau R, Leng N, Zill O, Sokol E, Liu G, Pavlick D, et al. Molecular determinants of response to PD-L1 blockade across tumor types. Nat Commun. 2021;12:3969. Available from: https://doi.org/10.1038/s41467-021-24,112-w Accessed 11 Oct 2021. 10.1038/s41467-021-24,112-w

[47]

Wang Y, Jiao X, Li S, Chen H, Wei X, Liu C, et al. Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer. Cancer Biol Med. 2021. Available from: https://doi.org/10.20892/j.issn.2095-3941.2020.0708 China Anti-cancer Association. Accessed 15 Feb 2022. 10.20892/j.issn.2095-3941.2020.0708

[48]

Fahmy O, Alhakamy NA, Khairul-Asri MG, Ahmed OAA, Fahmy UA, Fresta CG, et al. Oncological response and predictive biomarkers for the checkpoint inhibitors in castration-resistant metastatic prostate cancer: a systematic review and meta-analysis. J Pers Med. 2022;12:8. Available from: https://doi.org/10.3390/jpm12010008 MDPI. Accessed 13 Feb 2022. 10.3390/jpm12010008

[49]

Joshi M, Grivas P, Mortazavi A, Monk P, Clinton SK, Sue-Ann Woo M, et al. Alterations of DNA damage response genes correlate with response and overall survival in anti-PD-1/PD-L1-treated advanced urothelial cancer. Cancer Med. 2020;9:9365–72 Blackwell Publishing Ltd. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7774722/. Accessed 19 Aug 2021. 10.1002/cam4.3552

[50]

Mouw KW, Goldberg MS, Konstantinopoulos PA, D’Andrea AD. DNA damage and repair biomarkers of immunotherapy response. Cancer Discov. 2017;7:675–93 American Association for Cancer Research Inc. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5659200/. Accessed 11 Oct 2021. 10.1158/2159-8290.cd-17-0226

Showing 50 of 252 references

Metrics

68

Citations

252

References

Details

Published: Sep 07, 2022
Vol/Issue: 41(1)
License: View

Authors

School of Aeronautics and Astronautics, University of Electronic Science and Technology of China,Chengdu,611731

A

Anqi Lin

Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China.

National Center for Biotechnology Information

P

Peng Luo

Funding

Natural Science Foundation of Guangdong Province Award: 2018A030313846

Science and Technology Planning Project of Guangdong Province Award: 2019A030317020

Innovative Research Group Project of the National Natural Science Foundation of China Award: 81802257

Cite This Article

Congqi Shi, Kaiyu Qin, Anqi Lin, et al. (2022). The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy. Journal of Experimental & Clinical Cancer Research, 41(1). https://doi.org/10.1186/s13046-022-02469-0

The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy

You May Also Like